Biology of obsessive–compulsive disorder
The biology of obsessive-compulsive disorder(OCD) refers biologically based theories about the mechanism of OCD. Cognitive models generally fall into the category of executive dysfunction or modulatory control. Neuroanatomically, functional and structural neuroimaging studies implicate the prefrontal cortex (PFC), basal ganglia (BG), insula, and posterior cingulate cortex (PCC). Genetic and neurochemical studies implicate glutamate and monoamine neurotransmitters.
The cortico-basal ganglia-thalamo-cortical loop (CBGTC) model is based on the observation that the basal ganglia loops related to the OFC and ACC are implicated in OCD by neuroimaging studies, although the directionality of volumetric and functional changes is not consistent. Causal evidence from OCD secondary to neuropsychiatric disorders supports the CBGTC model. Obsessions may arise from failure of the circuit to gate information that is normally implicitly processed, leading to representation in explicit processing systems such as the dlPFC and hippocampus, and thereby resulting in obsessions.
Abnormal affect in OCD has been hypothesized to result from dysfunction in the OFC, ventral striatum, and amygdala. OCD is characterized by high levels of anxiety, high rates of comorbidity with major depressive disorder, and blunted response to reward. This is reflected by reduced amygdala and ventral striatum response to positive stimuli, and elevated amygdala response to fearful stimuli. Furthermore, deep brain stimulation of the nucleus accumbens is an effective treatment of OCD, and symptom improvement correlates with reduced binding of dopamine receptors. The reduced binding, due to the ability of the radioligand tracers to be displaced by endogenous dopamine, is taken to reflect increased basal dopamine release. Affective dysregulation due to blunted reward, and elevated fear sensitivity may promote compulsivity by assigning excessive motivational salience to avoidance behavior.
The ventral striatum is important in action selection, and receives inputs from the medial OFC that signal various aspects of value for stimulus association outcomes. By assigning abnormal values to certain behaviors, OFC may lead to compulsive behavior through modulating action selection in the ventral striatum. A number of abnormalities have been found in the OFC, including reduced volume, increased resting state activity, and reduced activity during cognitive tasks. The difference between resting and cognitive paradigms may be due to increased signal to noise ratio, a possible mechanism of aberrant valuation. OFC-striatum connectivity also predicts symptom severity, although the opposite has been found in some studies.
Besides abnormal valuation of stimuli or tasks, compulsions may be driven by dysfunction in error monitoring that leads to excessive uncertainty.
OCD has also been conceptualized as resulting from dysfunction in response inhibition, and fear extinction. While hyperactivation of the OFC as a whole during resting is observed in OCD, hyperactivation of the lateral OFC and hypoactivation of the mOFC is seen. This is congruent with the localization of fear/avoidance behaviors to the lOFC and emotional regulation to the mOFC. Hyperactivity of the dACC during monitoring task, along with hyperactivity of the lOFC and amygadala may all contribute to generating obsessions, reduced regulation by the mOFC may enable them.
One model suggests that obsessions do not drive compulsions, but are rather byproducts of compulsions, as evidenced by some studies reporting excessive reliance on habit. Dysfunctional habit based learning may be a driver behind neuroimaging studies of memory reporting increased hippocampus activity. The conscious processing of information that is normally implicitly processing may be the underlying cause of obsessions.
Functional neuroimaging studies have implicated multiple regions in OCD. Symptom provocation is associated with increased likelihood of activation in the bilateral orbitofrontal cortex(OFC), right anterior PFC, left dorsolateral prefrontal cortex (dlPFC), bilateral anterior cingulate cortex (ACC), left precuneus, right premotor cortex, left superior temporal gyrus(STG), bilateral external globus pallidus, left hippocampus, right insula, left caudate, right posterior cingulate cortex (PCC), and right superior parietal lobule. The medial portion of the orbitofrontal cortex connects with the paralimbic-limbic system, including the insular cortex, cingulate gryus, amygdala, and hypothalamus. This area is involved in encoding the representation of the value of an expected outcome, which is used to anticipate positive and negative consequences that are likely to follow a given action. During affective tasks hyperactivation has been observed in the ACC, insula and head of the caudate and putamen, regions implicated in salience, arousal, and habit. Hypoactivation during affective tasks is observed in the medial prefrontal cortex (mPFC) and posterior caudate, which are implicated in behavioral and cognitive control. During non-affective tasks, hyperactivation has been observed in the precuneus and PCC, while hypoactivation has been observed in the pallidum, ventral anterior thalamus and posterior caudate. An older meta analysis found hyperactivity in the OFC and ACC. An ALE meta analysis of various functional neuroimaging paradigms observed various abnormalities during Go/no go, interference, and task switching paradigms. Decreased likelihood of activation in right putamen and cerebellum was reported during Go/no go. During interference tasks, likelihood of activation was reported in the left superior frontal gyrus, right precentral gyrus, and left cingulate gyrus, to be decreased, and in the right caudate to be increased. Task switching was associated with extensive decreased likelihood of activation in the middle, medial, inferior, superior frontal gyri, caudate, cingulate and precuneus. A separate ALE meta analysis found consistent abnormalities in orbitofrontal, striatal, lateral frontal, anterior cingulate, middle occipital and parietal, and cerebellar regions.
Differences in grey matter, white matter and structural connectivity have been observed in OCD. One meta-analysis reported grey matter increases in the bilateral lenticular nuclei, and grey matter decreases in the ACC and mPFC. Another meta-analysis reported that global volumes are not decreased, but the left ACC and OFC demonstrate decreased volume, while the thalamus but not basal ganglia have increased volumes. An ALE meta analysis found increased grey matter in the left postcentral gyrus, middle frontal region, putamen, thalamus, left ACC, and culmen, while decreased grey matter was reported in the right temporal gyrus and left insula extending to the inferior frontal gyrus.
Overlapping abnormalities in white matter volume and diffusivity have been reported. Increased white matter volume and decreased Fractional anisotropy has been observed in anterior midline tracts, interpreted as indicating increased crossings. However, given these effects were most pronounced in medicated adults, it is possible that medication plays a role An ALE meta analysis has observed increased FA in the superior longitudinal fasiculus and corpus callosum, and decreased FA in inferior longitudinal and cingulum fibers.
Glutamate, an excitatory neurotransmitter has been implicated in OCD. MRS studies have observed decreased Glx in the striatum, an indicator of glutamate, glutamine and GABA. Increased Glx has been reported in the ACC as well. Furthermore, increased Cerebrospinal fluid(CSF) glutamate and glycine have been found. Various preclinical models have supported glutamate signaling dysfunction in OCD, and treatment with glutaminergic agents such as Riluzole has been reported to be efficacious.
Reduced dopamine D1 receptor (D1) and dopamine D2 receptor (D2) have been reported in the striatum in people with OCD, along with both increased and decreased reports of dopamine transporter (DAT) binding. While antipsychotics are sometimes used to treat refractory OCD, they frequently fail in treating or exacerbate OCD symptoms. Furthermore psychostimulants are sometimes used to treat OCD. Treatment with deep brain stimulation is effective in OCD, and response correlates with increased dopamine in the nucleus accumbens. Combined this evidence suggests that OCD may be associated with both increased and decreased dopamine signaling, or that a unidirectional model may not be adequate.
Drug challenge studies have implicated 5-HT2A and 5-HT2A in OCD. Administration of meta-Chlorophenylpiperazine(mCPP), a non selective serotonin(5-HT) release and receptor agonist with a preference for 5-HT2C has been reported to exacerbate OCD symptoms. Psylocibin, a 5-HT2C, 5-HT2A and 5-HT1A receptor agonist has been associated with acute improvement of OCD symptoms. In vivo neuroimaging has found abnormalities with 5-HT2A and Serotonin transporter(5-HTT). Inconsistent binding potentials have been observed for 5-HT2A, with both decreased and increased and binding potentials being reported. Inconsistent results have been reported in with respect to 5-HTT as well, with increased, decreased and no changes being reported.
Estrogen and OCD
Aromatase is an enzyme expressed in several gonadic tissue sites. It is the rate limiting step in the conversion of androgens to estrogen. This conversion can significantly impact estrogen levels in brain areas. These OCD-linked effects have been demonstrated by Aromatase knockout mice (ArKO), who lack a functional enzyme to convert androgens to estrogen. This ArKO knockout strategy has provided a model to examine the physiological impact of lower than normal amounts of estrogen.
Studies with ArKO mice have been used to show that varying levels of estrogen affect the onset of Obsessive Compulsive Disorder (OCD) behaviors. Lower amounts of estrogen are associated with an increase of OCD behaviors in males more than females.
Variation in estrogen can lead to increased levels of OCD symptoms within women as well. The disorder itself has a later onset in women, and tends to show two distinct peaks of onset. The first peak occurs around puberty and the second around the age of childbearing. These peaks correlate with time periods where estrogen levels are highest in women.
- Friedlander, L; Desrocher, M (January 2006). "Neuroimaging studies of obsessive-compulsive disorder in adults and children". Clinical Psychology Review. 26 (1): 32–49. doi:10.1016/j.cpr.2005.06.010. PMID 16242823.
- Maia, TV; Cooney, RE; Peterson, BS (2008). "The neural bases of obsessive-compulsive disorder in children and adults". Development and Psychopathology. 20 (4): 1251–83. doi:10.1017/S0954579408000606. PMC 3079445. PMID 18838041.
- Koen, Nastassja; Stein, Dan. "Obsessive-Compulsive Disorder". In Zigmond, M; Rowland, L; Coyle, J (eds.). Neurobiology of Brain Disorders. Elsevier. p. 628.
- Wood, J; Ahmari, SE (2015). "A Framework for Understanding the Emerging Role of Corticolimbic-Ventral Striatal Networks in OCD-Associated Repetitive Behaviors". Frontiers in Systems Neuroscience. 9: 171. doi:10.3389/fnsys.2015.00171. PMC 4681810. PMID 26733823.
- Barahona-Corrêa, JB; Camacho, M; Castro-Rodrigues, P; Costa, R; Oliveira-Maia, AJ (2015). "From Thought to Action: How the Interplay Between Neuroscience and Phenomenology Changed Our Understanding of Obsessive-Compulsive Disorder". Frontiers in Psychology. 6: 1798. doi:10.3389/fpsyg.2015.01798. PMC 4655583. PMID 26635696.
- Milad, MR; Rauch, SL (January 2012). "Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways". Trends in Cognitive Sciences. 16 (1): 43–51. doi:10.1016/j.tics.2011.11.003. PMC 4955838. PMID 22138231.
- Gillan, CM; Sahakian, BJ (January 2015). "Which is the driver, the obsessions or the compulsions, in OCD?". Neuropsychopharmacology. 40 (1): 247–8. doi:10.1038/npp.2014.201. PMC 4262900. PMID 25482176.
- Rotge, Jean-Yves; Guehl, Dominique; Dilharreguy, Bixente; Cuny, Emmanuel; Tignol, Jean; Bioulac, Bernard; Allard, Michele; Burbaud, Pierre; Aouizerate, Bruno (3 March 2017). "Provocation of obsessive–compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies". Journal of Psychiatry & Neuroscience. 33 (5): 405–412. ISSN 1180-4882. PMC 2527721. PMID 18787662.
- Rasgon, A; Lee, WH; Leibu, E; Laird, A; Glahn, D; Goodman, W; Frangou, S (October 2017). "Neural correlates of affective and non-affective cognition in obsessive compulsive disorder: A meta-analysis of functional imaging studies". European Psychiatry. 46: 25–32. doi:10.1016/j.eurpsy.2017.08.001. PMID 28992533.
- Whiteside, Stephen P.; Port, John D.; Abramowitz, Jonathan S. (2004). "A meta–analysis of functional neuroimaging in obsessive–compulsive disorder". Psychiatry Research: Neuroimaging. 132 (1): 69–79. doi:10.1016/j.pscychresns.2004.07.001. PMID 15546704.
- Eng, GK; Sim, K; Chen, SH (May 2015). "Meta-analytic investigations of structural grey matter, executive domain-related functional activations, and white matter diffusivity in obsessive compulsive disorder: an integrative review". Neuroscience and Biobehavioral Reviews. 52: 233–57. doi:10.1016/j.neubiorev.2015.03.002. PMID 25766413.
- Menzies, L; Chamberlain, SR; Laird, AR; Thelen, SM; Sahakian, BJ; Bullmore, ET (2008). "Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited". Neuroscience and Biobehavioral Reviews. 32 (3): 525–49. doi:10.1016/j.neubiorev.2007.09.005. PMC 2889493. PMID 18061263.
- Radua, J; Mataix-Cols, D (November 2009). "Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder". The British Journal of Psychiatry. 195 (5): 393–402. doi:10.1192/bjp.bp.108.055046. PMID 19880927.
- Rotge, JY; Guehl, D; Dilharreguy, B; Tignol, J; Bioulac, B; Allard, M; Burbaud, P; Aouizerate, B (1 January 2009). "Meta-analysis of brain volume changes in obsessive-compulsive disorder". Biological Psychiatry. 65 (1): 75–83. doi:10.1016/j.biopsych.2008.06.019. PMID 18718575.
- Radua, J; Grau, M; van den Heuvel, OA; Thiebaut de Schotten, M; Stein, DJ; Canales-Rodríguez, EJ; Catani, M; Mataix-Cols, D (June 2014). "Multimodal voxel-based meta-analysis of white matter abnormalities in obsessive-compulsive disorder". Neuropsychopharmacology. 39 (7): 1547–57. doi:10.1038/npp.2014.5. PMC 4023155. PMID 24407265.
- Naaijen, J; Lythgoe, DJ; Amiri, H; Buitelaar, JK; Glennon, JC (May 2015). "Fronto-striatal glutamatergic compounds in compulsive and impulsive syndromes: a review of magnetic resonance spectroscopy studies". Neuroscience and Biobehavioral Reviews. 52: 74–88. doi:10.1016/j.neubiorev.2015.02.009. PMID 25712432.
- Pittenger, C; Bloch, MH; Williams, K (December 2011). "Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment". Pharmacology & Therapeutics. 132 (3): 314–32. doi:10.1016/j.pharmthera.2011.09.006. PMC 3205262. PMID 21963369.
- Wu, K; Hanna, GL; Rosenberg, DR; Arnold, PD (February 2012). "The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder". Pharmacology Biochemistry and Behavior. 100 (4): 726–35. doi:10.1016/j.pbb.2011.10.007. PMC 3437220. PMID 22024159.
- Jacobs, edited by Christian P. Müller, Barry (2009). Handbook of the behavioral neurobiology of serotonin (1st ed.). London: Academic. pp. 549–552. ISBN 978-0-12-374634-4.CS1 maint: Extra text: authors list (link)
- Boon, Wah Chin; Horne, Malcolm K. (2011). "Aromatase and its inhibition in behaviour, obsessive compulsive disorder and parkinsonism". Steroids. 76 (8): 816–9. doi:10.1016/j.steroids.2011.02.031. PMID 21477611.
- Lochner, Christine; Hemmings, Sian M.J.; Kinnear, Craig J.; Moolman-Smook, Johanna C.; Corfield, Valerie A.; Knowles, James A.; Niehaus, Dana J.H.; Stein, Dan J. (2004). "Gender in obsessive–compulsive disorder: Clinical and genetic findings". European Neuropsychopharmacology. 14 (2): 105–13. doi:10.1016/s0924-977x(03)00063-4. PMID 15013025.
- Brandes, M.; Soares, C. N.; Cohen, L. S. (2004). "Postpartum onset obsessive-compulsive disorder: Diagnosis and management". Archives of Women's Mental Health. 7 (2): 99–110. doi:10.1007/s00737-003-0035-3. PMID 15083345.